Systematic review and meta-analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine by Luksanapruksa, Panya et al.




Systematic review and meta-analysis of en bloc
vertebrectomy compared with intralesional
resection for giant cell tumors of the mobile spine
Panya Luksanapruksa
Mahidol University, Faculty of Medical Technology
Jacob M. Buchowski




University of Arkansas at Little Rock
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Luksanapruksa, Panya; Buchowski, Jacob M.; Singhatanadgige, Weerasak; and Bumpass, David B., ,"Systematic review and meta-
analysis of en bloc vertebrectomy compared with intralesional resection for giant cell tumors of the mobile spine." Global Spine
Journal.6,8. 798-803. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5931
Systematic Review and Meta-analysis of En Bloc
Vertebrectomy Compared with Intralesional
Resection for Giant Cell Tumors of the Mobile Spine
Panya Luksanapruksa1 Jacob M. Buchowski2 Weerasak Singhatanadgige3 David B. Bumpass4
1Department of Orthopedic Surgery, Faculty of Medicine Siriraj
Hospital, Mahidol University, Bangkok, Thailand
2Department of Orthopedic Surgery, Washington University School of
Medicine in St. Louis, St. Louis, Missouri, United States
3Department of Orthopedic Surgery, Chulalongkorn University and
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
4Department of Orthopaedic Surgery, University of Arkansas for
Medical Sciences, Little Rock, Arizona, United States
Global Spine J 2016;6:798–803.
Address for correspondence Jacob M. Buchowski, MD, MS, Professor
of Orthopaedic and Neurological Surgery, Department of Orthopedic
Surgery, Washington University in St. Louis, Barnes-Jewish Institute of
Health, 425 S. Euclid Avenue, Campus Box 8233, St. Louis, MO 63110,
United States (e-mail: buchowskij@wustl.edu).
Introduction
Spinal giant cell tumors (SGCTs) are locally aggressive benign
bone tumors that can occur anywhere along the spine. SGCTs
account for approximately 2 to 3% of all giant cell tumors (GCTs).
Its incidence is higher in females, the sacral region, and patients
aged 20 to 40 years.1,2 SGCTs are usually discovered at Enneking
stage 2 (fully osteolytic lesion with well-deﬁned borders) and
stage 3 (ill-deﬁned border lesion eroding and extending beyond
cortex into the surrounding soft tissue).3 Donthineni et al
reported that 13.7% of SGCTs eventually metastasize to the











Abstract Study Design Systematic review and meta-analysis.
Objective To compare the recurrence and perioperative complication rate of en bloc
vertebrectomy (EV) and intralesional resection (IR) in the giant cell tumor of the mobile
spine (SGCT).
Methods We systematically searched publications in the PubMed and Embase data-
bases for reports of SGCTs, excluding the sacrum. Two reviewers independently
assessed all publications. A meta-analysis was performed using local recurrence and
postoperative complications as the primary outcomes of interest.
Results There were four articles reporting recurrence and two articles reporting
postoperative complications. All included articles were case series. In all, 91 patients
were included; 49 were treated with IR and 42 were treated with EV. Local recurrence
rates were 36.7 and 9.5% in the IR and EV groups, respectively. Rates of postoperative
complications were 36.4% with IR and 11.1% with EV. Overall, patients treated with EV
not only had a lower recurrence rate (relative risk [RR] 0.22; 95% conﬁdence interval [CI]
0.09 to 0.52) but also had a lower postoperative complication rate (RR 0.34; 95% CI 0.07
to 1.52) compared with IR.
Conclusions Based on the limited data obtained from systematic review, SGCT
patients treated with EV had a lower recurrence rate and fewer postoperative
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The goals of SGCT treatment are tumor removal, spinal
stability, and neural tissue decompression. The choices of
operative treatment are en bloc vertebrectomy (EV) or
intralesional resection (IR).5,6 Because of the proximity of
vital structures to the vertebrae, EVmay be too damaging to
undertake in some cases. Therefore, IR might be the
alternative choice in selected cases.7 Numerous adjuvant
therapies can be employedwith either of these two surgical
strategies.
Because previous studies have provided inconclusive
results, we compared the overall recurrence rates and
complications between IR with or without adjuvant
therapy against EV in patients with SGCT from published
case series.
Materials and Methods
Data Source and Search Strategy
Two independent reviewers (P.L., W.S.) performed a search
in October 2015 of all peer-reviewed relevant literature in
human patients using EMBASE and PubMed for studies
comparing IR versus EV treatment in patients with SGCT.
No language or date limitations were applied. The following
search terms were used: ((giant cell tumo) AND
((((((spine) OR spinal) OR vertebral) OR vertebra) NOT
sacrum) NOT craniocervical)) AND ((recurrence) OR
complicatio). Additional searches were performed by
using the reference lists from the retrieved studies that
were relevant to SGCT.
Inclusion and Exclusion Criteria
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses protocol was followed for data selection and
analysis. The inclusion criteria were randomized controlled
trials, observational studies, or case series in patients with
primary SGCT (excluding the sacrum), intervention (IR),
comparator (EV), and outcomes that reported local recur-
rence or incidence of postoperative complications. Studies
were excluded if they had fewer than three patients, multiple
GCT lesions, less than 6 months’ follow-up, recurrent tumors,
previous surgical resections, mixed reports with other tumor
types, or lack of speciﬁcity for time points of recurrence or
complications. Case reports, review articles, and technical
reports were also excluded. Both reviewers independently
screened abstracts and titles after removing duplicated pub-
lications. Then, thorough full-paper readingswere performed
of the studies that might meet the inclusion criteria to
determine ﬁnal inclusion. Disagreements were solved by
discussion for consensus.
The rates of local recurrence and postoperative compli-
cations were extracted directly from the original studies to
calculate risk ratios. Both reviewers extracted data inde-
pendently. The methodological quality of the included
studies was independently assessed by the two reviewers
using the Methodological Index for Nonrandomized Stud-
ies (MINORS) scale that allocates a maximum of 24 points
for comparability, exposure, quality of selection, and out-
come of study participants.8
We performed a meta-analysis using Review Manager
software (RevMan Version 5.1; Nordic Cochrane Center,
Copenhagen, Denmark). Risk ratios (RRs) and 95% conﬁdence
intervals (CIs) were used to evaluate the dichotomous out-
comes of incidence of local recurrence and complications.
Statistical heterogeneity was assessed using the Cochrane Q
test, with a p value set at 0.1 for signiﬁcance. Heterogeneity
between trials was evaluated based on an assigned I2 value
and substantial heterogeneity was represented by an I2 value
greater than 50%. The ﬁxed-effects model was used when the
effects were assumed to be homogenous. In the presence of
heterogeneity, we used a random-effect model. A funnel plot
with the test of Begg and Mazumdar was used to evaluate
publication bias.9–11 Sensitivity analysis was performed
by rejecting the studies with higher statistical heterogeneity.
A p value < 0.05 was considered statistically signiﬁcant.
Results
There were 507 abstracts (172 from PubMed and 335 from
EMBASE) identiﬁed through the database search. Of these,
122 publications were duplicates and thus a total of 385
unique abstracts were screened. Eighty-six abstracts were
selected for full review after 299 nonrelevant abstracts were
removed. Eighty-two reports were excluded for following
reasons: 3 had unclear data, 17 had multiple tumor types
reported, 7 had no surgery, 10 did not compare IR/EV, 4 had
recurrent tumors, 2 had multiple lesions, and 39 were non-
qualifying publications (review article, case report, technical
note, correspondence). The reviewers selected a total of four
studies for systematic review and meta-analysis of SGCT
recurrence (►Fig. 1). The details of the included studies are
summarized in ►Table 1.
All four studies selected for meta-analysis of recurrence
were retrospective case series that showed lower rates of
recurrence and postoperative complications with EV as com-
pared with IR.2,5,12,13 However, EV was not performed prior
to 1991 in the series by Boriani et al.2 The follow-up period
ranged from 19 to 328months. Most of the patients having IR
received postoperative radiation therapy ranging from 30 to
50 Gy in 10 to 20 fractions.2 Both the series by Boriani et al
and the series by Junming et al had one patient death in the
early postoperative period; these patients were not included
in their analyses because local recurrence could not be
assessed.2,13 We excluded one case in the series of Junming
et al of an SGCT lesion located solely in the posterior elements
of C7.
In total, the included series contained 91 patients with
primary SGCT. Of these patients, 42 underwent EV and 49
underwent IR. Overall recurrence rates for SGCT treated with
IR versus EV were 36.7% (18 of 49 patients) versus 9.5% (4 of
442 patients), respectively. The pooled RR for tumor recur-
rencewas 0.22 (95% CI 0.09 to 0.52; p ¼ 0.0006; homogeneity
I2 0%), suggesting that IR was associated with a higher rate of
recurrence (►Fig. 2).
Two of these studies also qualiﬁed for meta-analysis of
postoperative complications, for a total of 29 patients.12,13 In
the IR group, 4 of 11 patients experienced complications
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(including screw loosening, graft fracture, intrathoracic
hematoma, and respiratory failure) versus 2 of 18 patients
in the EVgroup (including intraoperative bleeding/abdominal
wall weakness and postoperative cerebrospinal ﬂuid leak-
age). Junming et al reported an intraoperative unilateral
vertebral artery injury in two patients in the EV group that
required unilateral ligation; however, these patients experi-
enced no postoperative deﬁcits and were not counted as
postoperative complications in the analysis.13
The rates of postoperative complications for SGCT treated
with IR versus EV were 36.4% (4 of 11) versus 11.1% (2 of 18),
respectively. The pooled RR for postoperative complications
was 0.34 (95% CI, 0.07 to 1.52; p ¼ 0.16; homogeneity
I2 ¼ 0%; ►Fig. 3). Therefore, there was a lower rate of
postoperative complications associated with EV compared
with IR, but without statistical signiﬁcance.
The mean MINORS scores of the included studies were
14.75  1.50 (►Table 2). Funnel plotting for bias demonstrat-
ed that all four studies fell within the funnel, all near the
midline (►Fig. 4).
Discussion
GCTs of the mobile spine are classiﬁed as locally aggressive
benign tumors, but they have a high overall reported rate of
recurrence (11 to 45%).14–16 Case series have been reported,
suggesting that total tumor removal must be performed to
prevent local recurrence and pulmonary metastases. Many
single case reports showed no local recurrence after verte-
brectomy in the cervical, thoracic, and lumbar regions.17–21
However, because of the complexity of spinal anatomy and
the proximity to neural elements, vertebrectomy may
require sacriﬁce of vital structures causing signiﬁcant
and permanent postoperative morbidity. Other series
have reported the efﬁcacy of IR with adjuvant therapy for
preventing local recurrence, a technique that arguably
would produce lower complication rates and less morbid-
ity.22–24 Most of these studies had limited numbers of
patients. Therefore, our objective was to systematically
review studies comparing the efﬁcacy of SGCT operative
treatment and to increase statistical power by performing a
meta-analysis.
EV has reported local recurrence rates of 0 to 14%, and IR
has recurrence rates of 0 to 71%.2,5,12,13,17–21,25–27 Our meta-
analysis produced pooled local recurrence rates of 9.5% for EV
and 36.7% for IR, a statistically signiﬁcant fourfold higher
recurrence rate. This difference existed even with the use of
adjuvant treatments in patients having IR.
Postoperative complication rates have been reported for
up to 24% of patients after EV,2,5,12,13 and up to 80% after
IR.2,5,12,13,16,22,25,26 This study demonstrated that patients
having IR had a higher rate of postoperative complications
(36.4%) compared with patients having EV (11.1%), but this
difference did not reach signiﬁcance. Thereweremany factors
that affected postoperative complications including comor-
bidities, severity of disease, follow-up period, adjuvant ther-
apy, and tumor location. Explanations as to why EV had a
lower complication risk than IR may include selective bias
(surgeons preferred EV in patients with fewer comorbidities,
less-extensive tumor extension, and younger age), exclusion
of studies (several studies were excluded because they only
reported IR results), or underreporting of complications in
the EV group.
None of the included studies reported details of comor-
bidities. There were no differences in overall follow-up
duration or tumor location, but the use of adjuvant radiation
varied in the two studies reporting its use in IR.2,13 There was
no difference in the local recurrence rate between patients
having IR receiving radiation (35%) and those not undergoing
radiation (21%). Because the use of adjuvant radiation was in
part determined by the surgeons’ decision, the data may be
biased.
The methodological quality of the included studies dem-
onstrated MINORS scores between 14 and 17, slightly higher
than the mean reported scores for nonrandomized surgical
studies. Our assessment of bias demonstrated that all the
included studies fell within the funnel plot, although the
relatively small number of studies did not result in a wide
distribution within the funnel.
Fig. 1 Flow diagram demonstrating study search results.
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Several limitations should be considered when interpret-
ing these ﬁndings. First, no randomized controlled trials of
SGCT have been conducted because of the relative rarity of
SGCT, ethical issues, tumor proximity to surrounding neural
structures, and high technical skill and experience required to
perform EV. Second, only a few cases series met the inclusion
criteria for themeta-analysis, and all were retrospective; only
two studies reported the postoperative complication rates.
Third, there likely was a physician selection bias in choosing
the type of operation because less aggressive lesions in
healthier patients were perhaps more likely to be treated
with EV. Conversely, physicians may have preferred IR in
patients who had severe comorbidities or extensive lesions.
EV in the cervical spine can be a signiﬁcant challenge because
Table 1 Characteristics of included studies




Boriani et al (2012)2
IR EV IR EV IR EV IR EV
Study design Case series Case series Case series Case series
Mean age (y) 32 (22–68) 36 (17–66) 36 (13–64) 31 (11–61)
Overall follow-up 8.25 (2.5–12) y 67.8 (36–124) mo 29 (6–144) mo 145 (19–328) mo
Amount of
follow-up
9/9 20/22 13/13 49/50
Follow-up 2.5–10 y 4.5–12 y 45–124 mo 36–78
mo
29–107 mo 6–144 mo 19–328 mo 48–213 mo
Number of
cases
4 5 7 13 2 11 36 13
Comorbidity NA NA NA NA NA NA NA NA
Location (n) T (4) T (6) C (7) C (13) C (1), L (1) C (4), T (2),
L (5)
C (6), T (17),
L (13)




NA NA NA NA 1/2 3/11 No No
Adjuvant RT No No 6/7 12/13 No 2/11 17/36 No
Free margin
after EV
– NA – NA – NA – 12/13
Abbreviations: C, cervical spine; EV, en bloc vertebrectomy; IR, intralesional resection; L, lumbar spine; NA, no mention; PAE, preoperative arterial
embolization; RT, radiotherapy; S, sacrum; T, thoracic spine.
aOnly mobile spine counted.
Fig. 3 Forest plot to illustrate risk ratio in postoperative complications between en bloc vertebrectomy and intralesional resection. Abbreviations:
CI, conﬁdence interval; M-H, Mantels-Haenszel methods.
Fig. 2 Forest plot to illustrate risk ratio in recurrence between vertebrectomy and intralesional resection. Abbreviations: CI, conﬁdence interval;
M-H, Mantels-Haenszel methods.
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of surrounding vital anatomy and neurologic risk. IR may be
selected in these cervical tumors in an attempt to prevent
devastating complications and severe disability. Fourth, dif-
ferent adjuvant therapy protocols were used in the patients
having IR, including radiotherapy and preoperative emboli-
zation. Additionally, in the series by Martin and McCarthy,
two patients having EV had follow-up periods less than 1 year
(6 and 10 months, respectively). Both of them had no recur-
rence at the ﬁnal evaluation. Because of the short follow-up
time, the incidence of local recurrence may be underesti-
mated in this report. Thus, themeta-analysis does not provide
any data regarding which adjuvant treatments are more
efﬁcacious when used with IR. Finally, included studies had
variable follow-up durations and protocols.
Xu et al reported on factors inﬂuencing the recurrence risk
in 102 patients with SGCT. Their multivariate analysis found
that IR had a hazard ratio of 3.02 when compared with EV
(p ¼ 0.02). However, their report does not speciﬁcally state
the recurrence-free intervals for the patients in each surgical
treatment group, and thuswe could not include their patients
in our meta-analysis. However, their report provides infor-
mative ﬁndings on a relatively large series of patients, and
their results mirror ours.28
In conclusion, this meta-analysis demonstrated that EV
for GCTs of the mobile spine was associated with a signiﬁ-
cantly reduced risk for future recurrence. In addition, EV
had a lower postoperative complication risk, although this
ﬁnding did not reach signiﬁcance. Further multicenter
prospective cohort studies are needed to strengthen the
evidence for how best to treat these challenging tumors.
Surgeons must carefully evaluate patients with SGCT on a
case-by-case basis, weighing the morbidity of the surgery
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Clearly stated aim 2 1 2 2
Inclusion of consecutive patients 1 2 2 2
Prospective collection of data 0 0 0 0
End points appropriate to the aim of the study 2 1 2 2
Unbiased assessment of the study end point 0 0 0 0
Follow-up period appropriate to the aim of the study 2 2 2 2
Loss to follow up less than 5% 2 2 2 2
Prospective calculation of the study size 0 0 0 0
Adequate control group 2 1 1 1
Contemporary groups 2 2 1 0
Baseline equivalence of groups 2 2 1 1
Adequate statistical analyses 2 1 1 2
Total 17 14 14 14
aScored 0 (not reported), 1 (reported but inadequate), or 2 (reported and adequate).
Fig. 4 Funnel plot for the publication bias test of the four eligible studies.
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